{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T01:18:07Z","timestamp":1781659087040,"version":"3.54.5"},"reference-count":21,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Acromegaly is a rare, chronic, systemic, and progressive disease characterized by an excess secretion of growth hormone (GH) and increased circulating insulin-like growth factor 1 (IGF-1) concentrations, typically due to a macroadenoma in the pituitary gland. Both GH and IGF-1 are implicated in cancer promotion based on experimental and epidemiological data, but research findings remain conflicting and population-based data are scarce. Although there is a high mortality rate among acromegalic patients due to cardiovascular diseases, cancer is the third leading cause of death. Aim: The aim of the present study was to assess the risk of different types of cancer in acromegaly and the impact of changes in disease control and patient outcomes over time. Methods: Patients diagnosed with acromegaly at the Ankara University Ibn-i Sina Hospital Endocrinology and Metabolic Diseases Department between 2015 and 2019 were included in this study. Data including demographic data, history of cancer, size of adenoma (micro or macro), serum IGF-1 and GH levels at the time of diagnosis, serum prostate-specific antigen (PSA), thyroid ultrasonography, and, if needed, thyroid fine needle aspiration cytology (TFAC), colonoscopy, and mammography results were collected from patient records retrospectively. Results: We screened 83 patients, and 78 patients with the compensatory data (female\/male: 39\/39, 50%\/50%) were included. The mean age of patients was 49.4 \u00b1 11.9 years and 41.7 \u00b1 12.1 years at the time of diagnosis. The median duration of follow-up was 72 (12\u2013420) months. Periodic thyroid ultrasonography was performed in 65\/78 (83.3%) of the patients, and a colonoscopy and mammography were also conducted in 27\/78 (34.6%) and 32\/39 (82%) of the patients at least once over the course of the disease, respectively. Cancer was detected in 17\/78 (21.7%) of the patients; 11\/78 (14.1%) of them had well-differentiated thyroid cancer and 2\/39 (5.1%) had breast cancer. Prostate cancer, renal cell carcinoma, pancreatic cancer, malignant chordoma, schwannoma, and colon cancer were detected in one patient each. The increased cancer risk in acromegalic patients did not correlate with age, sex, age at diagnosis, time to diagnosing acromegaly, duration of acromegaly, GH and IGF-1 levels at diagnosis, pituitary adenoma size, or Ki-67 levels. Conclusions: Cancer was detected in 21.7% of the acromegaly patients, 14.1% of whom had well-differentiated thyroid cancer. In this study, we demonstrated that thyroid cancer is the most common malignancy in Turkish acromegalic patients, consistent with the results of previous studies. The increased cancer risk in acromegalic patients did not correlate with age, sex, age at diagnosis, time to diagnosing acromegaly, duration of acromegaly, or GH and IGF-1 levels at diagnosis.<\/jats:p>","DOI":"10.3390\/jcm15041573","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:22:46Z","timestamp":1771320166000},"page":"1573","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cancer Risk in Patients with Acromegaly: Insights from a Single Center in Ankara"],"prefix":"10.3390","volume":"15","author":[{"given":"Murat","family":"Cinel","sequence":"first","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Demir","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rovsan","family":"Hasenov","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7695-9611","authenticated-orcid":false,"given":"Sule","family":"Canlar","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caglar","family":"Keskin","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1186-2960","authenticated-orcid":false,"given":"Asena","family":"G\u00f6k\u00e7ay Canpolat","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4718-0083","authenticated-orcid":false,"given":"Mustafa","family":"Sahin","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevim","family":"G\u00fcll\u00fc","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Demet","family":"Corapcioglu","sequence":"additional","affiliation":[{"name":"Endocrinology Department, Ankara University Faculty of Medicine, 06000 Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management","volume":"25","author":"Colao","year":"2004","journal-title":"Endocr. Rev."},{"key":"ref_2","first-page":"2730","article-title":"Mortality and Cancer Incidence in Acromegaly: A Retrospective Cohort Study","volume":"83","author":"Orme","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_3","first-page":"395","article-title":"Acromegaly and cancer risk: A cohort study in Sweden and Denmark","volume":"13","author":"Baris","year":"2002","journal-title":"Cancer Causes Control"},{"key":"ref_4","first-page":"299","article-title":"Increased thyroid cancer risk in acromegaly","volume":"17","author":"Dagdelen","year":"2014","journal-title":"Endocr. Abstr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1054\/ghir.2000.0171","article-title":"Does the GH\u2013IGF axis play a role in cancer pathogenesis?","volume":"10","author":"Cohen","year":"2000","journal-title":"Growth Horm. IGF Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0928-4680(01)00078-5","article-title":"Acromegaly and the risk of cancer","volume":"8","author":"Marek","year":"2001","journal-title":"Pathophysiology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3803\/EnM.2023.601","article-title":"Acromegaly and Bone: An Update","volume":"38","author":"Giustina","year":"2023","journal-title":"Endocrinol. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1159\/000505332","article-title":"Natural History of Acromegaly: Incidences, Re-operations, Cancers, and Mortality Rates in a National Cohort","volume":"110","author":"Wu","year":"2019","journal-title":"Neuroendocrinology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/archinte.1991.00400080113022","article-title":"Benign and Malignant Tumors in Patients with Acromegaly","volume":"151","author":"Barzilay","year":"1991","journal-title":"Arch. Intern. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1507\/endocrj.47.SupplMarch_S57","article-title":"Incidence of Malignant Tumors in Patients with Acromegaly","volume":"47","author":"Higuchi","year":"2000","journal-title":"Endocr. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1210\/jc.2015-2372","article-title":"The Incidence of Cancer Among Acromegaly Patients: Results from the German Acromegaly Registry","volume":"100","author":"Petroff","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1210\/endo-119-2-940","article-title":"Insulin-Like Growth Factor-I Stimulates the Growth of Rat Thyroid Cells in Culture and Synergizes the Stimulation of Dna Synthesis Induced by TSH and Graves\u2032-IgG","volume":"119","author":"Tramontano","year":"1986","journal-title":"Endocrinology"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1210\/endo.139.4.5884","article-title":"Growth Hormone Stimulation of the Mitogen-Activated Protein Kinase Pathway Is Cell Type Specific","volume":"139","author":"Love","year":"1998","journal-title":"Endocrinology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1210\/er.2018-00166","article-title":"Growth Hormone\u2019s Links to Cancer","volume":"40","author":"Boguszewski","year":"2018","journal-title":"Endocr. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eem.10.73","article-title":"Role of the growth hormone\u2013IGF-1 axis in cancer","volume":"6","author":"Chhabra","year":"2011","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1530\/EJE-16-0178","article-title":"Management of Endocrine Disease: Acromegaly and cancer: An old debate revisited","volume":"175","author":"Boguszewski","year":"2016","journal-title":"Eur. J. Endocrinol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1210\/jc.2017-02457","article-title":"Cancer Incidence in Patients with Acromegaly: A Cohort Study and Meta-Analysis of the Literature","volume":"103","author":"Dal","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/j.1365-2265.2009.03619.x","article-title":"Increased cancer incidence in acromegaly\u2014A nationwide survey","volume":"72","author":"Sane","year":"2010","journal-title":"Clin. Endocrinol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wolinski, K., Czarnywojtek, A., and Ruchala, M. (2014). Risk of Thyroid Nodular Disease and Thyroid Cancer in Patients with Acromegaly\u2014Meta-Analysis and Systematic Review. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088787"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5152\/tjbh.2015.2869","article-title":"Turkish Ministry of Health, 2nd Turkish Medical General Assembly Clinical Oncology Study Group Report","volume":"12","author":"Ozmen","year":"2016","journal-title":"J. Breast Health"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Strzelec, M., Rolla, M., Kuliczkowska-P\u0142aksej, J., Ka\u0142u\u017cny, M., S\u0142oka, N., Wronowicz, J., Bolanowski, M., and Jawiarczyk-Przyby\u0142owska, A. (2024). Prevalence of Neoplasms in Patients with Acromegaly\u2014A Single-Center Polish Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13226847"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1573\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T09:44:01Z","timestamp":1771321441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/4\/1573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["jcm15041573"],"URL":"https:\/\/doi.org\/10.3390\/jcm15041573","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]}}}